1. Home
  2. APPS vs MRVI Comparison

APPS vs MRVI Comparison

Compare APPS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Turbine Inc.

APPS

Digital Turbine Inc.

HOLD

Current Price

$4.63

Market Cap

503.5M

Sector

Miscellaneous

ML Signal

HOLD

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

HOLD

Current Price

$3.65

Market Cap

449.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPS
MRVI
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
449.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
APPS
MRVI
Price
$4.63
$3.65
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$6.25
$4.58
AVG Volume (30 Days)
2.6M
1.5M
Earning Date
02-04-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$525,092,000.00
$192,435,000.00
Revenue This Year
$13.99
N/A
Revenue Next Year
$11.83
$9.04
P/E Ratio
N/A
N/A
Revenue Growth
6.82
N/A
52 Week Low
$1.40
$1.67
52 Week High
$8.28
$6.21

Technical Indicators

Market Signals
Indicator
APPS
MRVI
Relative Strength Index (RSI) 39.39 54.35
Support Level $4.57 $3.50
Resistance Level $5.13 $3.95
Average True Range (ATR) 0.22 0.18
MACD 0.04 -0.01
Stochastic Oscillator 23.08 48.03

Price Performance

Historical Comparison
APPS
MRVI

About APPS Digital Turbine Inc.

Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Share on Social Networks: